These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 32830792

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
    Yang L, Li M, Wang F, Zhen C, Luo M, Fang X, Zhang H, Zhang J, Li Q, Fu L.
    Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496
    [Abstract] [Full Text] [Related]

  • 3. Downregulation of microRNA let-7f mediated the Adriamycin resistance in leukemia cell line.
    Cao YX, Wen F, Luo ZY, Long XX, Luo C, Liao P, Li JJ.
    J Cell Biochem; 2020 Oct; 121(10):4022-4033. PubMed ID: 31793054
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
    Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV.
    Blood; 2003 Mar 15; 101(6):2368-73. PubMed ID: 12609962
    [Abstract] [Full Text] [Related]

  • 6. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy.
    Wu M, Liu X, Jin W, Li Y, Li Y, Hu Q, Chu PK, Tang G, Ping Y.
    J Control Release; 2017 May 10; 253():110-121. PubMed ID: 28302581
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis.
    Wang W, Niu S, Qiao L, Wei F, Yin J, Wang S, Ouyang Y, Chen D.
    Biomed Res Int; 2019 May 10; 2019():8727935. PubMed ID: 30886864
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
    Chen T, Wang C, Liu Q, Meng Q, Sun H, Huo X, Sun P, Peng J, Liu Z, Yang X, Liu K.
    Cancer Biol Ther; 2015 May 10; 16(1):106-14. PubMed ID: 25482933
    [Abstract] [Full Text] [Related]

  • 11. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
    Mashayekhi S, Yousefi B, Tohidi E, Darband SG, Mirza-Aghazadeh-Attari M, Sadighparvar S, Kaviani M, Shafiei-Irannejad V, Kafil HS, Karimian A, Jadidi-Niaragh F, Majidinia M.
    J Cell Biochem; 2019 Sep 10; 120(9):15719-15729. PubMed ID: 31087712
    [Abstract] [Full Text] [Related]

  • 12. Silencing of the CrkL gene reverses the doxorubicin resistance of K562/ADR cells through regulating PI3K/Akt/MRP1 signaling.
    Yu J, Chen WX, Xie WJ, Chen RW, Lin DQ, You WW, Ye WL, Zhang HQ, Lin DH, Xu JP.
    J Clin Lab Anal; 2021 Aug 10; 35(8):e23817. PubMed ID: 34114685
    [Abstract] [Full Text] [Related]

  • 13. [Reversal of multidrug-resistance in human leukemia cell line K562/A02 by tyrosine kinase inhibitors].
    Shan XY, Chen BA, Xia GH, Xu WL, Ding JH, Gao C, Sun YY, Wang J, Cheng J, Zhao G, Bao W, Song HH, Gao F, Wang F, Wang XM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb 10; 18(1):90-5. PubMed ID: 20137125
    [Abstract] [Full Text] [Related]

  • 14. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z, Ma C, Li P, Wu M, Ye S, Fu L, Xu J.
    Cell Commun Signal; 2019 Sep 01; 17(1):110. PubMed ID: 31472682
    [Abstract] [Full Text] [Related]

  • 15. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J, Zhang X, Wang F, Wang X, Yang K, Xu M, To KK, Li Q, Fu L.
    Oncotarget; 2015 Dec 29; 6(42):44643-59. PubMed ID: 26556876
    [Abstract] [Full Text] [Related]

  • 16. Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.
    Prado-Carrillo O, Arenas-Ramírez A, Llaguno-Munive M, Jurado R, Pérez-Rojas J, Cervera-Ceballos E, Garcia-Lopez P.
    Int J Mol Sci; 2022 Jul 13; 23(14):. PubMed ID: 35887063
    [Abstract] [Full Text] [Related]

  • 17. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
    Li X, Miao H, Zhang Y, Li W, Li Z, Zhou Y, Zhao L, Guo Q.
    Arch Toxicol; 2015 Jan 13; 89(1):121-36. PubMed ID: 24671465
    [Abstract] [Full Text] [Related]

  • 18. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.
    Yousefi B, Azimi A, Majidinia M, Shafiei-Irannejad V, Badalzadeh R, Baradaran B, Zarghami N, Samadi N.
    Tumour Biol; 2017 Oct 13; 39(10):1010428317716501. PubMed ID: 28978268
    [Abstract] [Full Text] [Related]

  • 19. Knockdown of HOXA10 reverses the multidrug resistance of human chronic mylogenous leukemia K562/ADM cells by downregulating P-gp and MRP-1.
    Yi YJ, Jia XH, Wang JY, Li YJ, Wang H, Xie SY.
    Int J Mol Med; 2016 May 13; 37(5):1405-11. PubMed ID: 27035504
    [Abstract] [Full Text] [Related]

  • 20. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
    Mukai M, Che XF, Furukawa T, Sumizawa T, Aoki S, Ren XQ, Haraguchi M, Sugimoto Y, Kobayashi M, Takamatsu H, Akiyama S.
    Cancer Sci; 2003 Jun 13; 94(6):557-63. PubMed ID: 12824882
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.